What does this research mean for the field?

SMTP-44D treatment significantly protects renal function in diabetic nephropathy by reducing serum creatinine and urinary albumin levels. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The aim is to evaluate the effects of SMTP-44D on renal function in a diabetic nephropathy model.

January 10, 2026Biological and Pharmaceutical Bulletin0 citationsOpen Access

SMTP-44D Exerts Renoprotective Effects against Diabetic Nephropathy via Its Anti-inflammatory and Antioxidant Action

TATaiki AwaneShowa University HSH Sasaki KSKeita ShibataShowa University

Key Result

SMTP-44D treatment significantly decreased serum creatinine and urinary albumin while protecting renal function in a diabetic nephropathy mouse model over 10 weeks.

Key Points

The aim is to evaluate the effects of SMTP-44D on renal function in a diabetic nephropathy model.
Used a diabetic nephropathy mouse model by nephrectomy of db/db mice.
Administered SMTP-44D over ten weeks from weeks 6 to 16.
Measured blood glucose, renal function parameters, inflammatory factors, and oxidative stress markers.
Conducted histopathological assessment of kidney tissue.
SMTP-44D did not impact blood glucose levels but significantly reduced serum creatinine and urinary albumin levels.
Decreased inflammatory and oxidative stress markers in the kidney tissue.
Histopathological analysis showed prevention of glomerulosclerosis and promotion of local regenerative tubule.

Structured PICO

Does SMTP-44D improve renal function and reduce inflammation and oxidative stress in a mouse model of diabetic nephropathy?

Population

6-week-old male db/db mice (type 2 diabetes model) with right kidney removed to induce diabetic nephropathy, and male C57BL/6J mice as controls (n=6-8 per group).

Intervention

SMTP-44D (0.3, 3, or 30 mg/kg) administered intraperitoneally every 2 days for 10 weeks.

Comparator

Normal saline intraperitoneally (DN control) or metformin 300 mg/kg orally daily.

Outcome

Renal function parameters (serum creatinine and urinary albumin), inflammatory factors (MCP-1, ICAM-1), oxidative stress markers (NOX-1), and histopathological characteristics (glomerulosclerosis and local regenerative tubule).surrogate

SMTP-44D exerts renoprotective effects in a diabetic nephropathy mouse model by suppressing inflammation and oxidative stress, independent of blood glucose lowering.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

Diabetic nephropathy (DN) is among the most serious diabetes-related microvascular complications, a disease with risks leading to end-stage kidney disease (ESKD). However, only limited DN treatment options are currently available. DN development and progression involve different pathological mechanisms, including inflammation and oxidative stress. Stachybotrys microspora is a fungus producing the triphenyl phenol SMTP-44D, which exhibits anti-inflammatory and antioxidant properties in several disease models. In this study, we aimed to evaluate the effects of SMTP-44D in a DN mouse model, which was created by removing the right kidney of 6-week-old db/db mice. We administered SMTP-44D for 10 weeks between weeks 6 and 16 of age to observe blood glucose levels, renal function parameters, inflammatory factors, oxidative stress markers, and histopathological characteristics. SMTP-44D treatment did not reduce blood glucose level but significantly decreased serum creatinine and urinary albumin as renal function parameters, monocyte chemoattractant protein-1, intercellular adhesion molecule-1, and nicotinamide adenine dinucleotide phosphate oxidase-1 as inflammation and oxidative stress in the kidney. In addition, histopathological assessment revealed its preventive effect against glomerulosclerosis and local regenerative tubule. Therefore, we discovered that SMTP-44D might protect renal function without affecting blood glucose level in DN possibly via suppression of inflammation and oxidative stress. In conclusion, SMTP-44D could be a potential DN treatment agent, even in patients with poor glycemic control.

Ask AI

Helpful

Bookmark

View Full Paper